#BEGIN_DRUGCARD DB04654

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H17NO

# Chemical_IUPAC_Name:
4-(piperidin-4-yl)butanal

# Chemical_Structure:
Not Available

# Creation_Date:
2007-09-11 11:49:11 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
4-PIPERIDIN-4-YLBUTANAL

# HET_ID:
C1R

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H17NO/c11-8-2-1-3-9-4-6-10-7-5-9/h8-10H,1-7H2

# InChI_Key:
InChIKey=HADYAKDSDIXWOF-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4654

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
155.2374

# Molecular_Weight_Mono:
155.131014171

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.75

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
1.98e+00 g/l

# Primary_Accession_No:
DB04654

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
11840929

# PubChem_Substance_ID:
46507808

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O=CCCCC1CCNCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:34 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PRSS1

# Drug_Target_1_GenBank_ID_Gene:
M22612

# Drug_Target_1_GenBank_ID_Protein:
521216

# Drug_Target_1_GeneCard_ID:
PRSS1

# Drug_Target_1_Gene_Name:
PRSS1

# Drug_Target_1_Gene_Sequence:
>744 bp
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA

# Drug_Target_1_General_Function:
Involved in protease activity

# Drug_Target_1_General_References:
10204851	Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le Bodic L: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet. 1999 Mar;36(3):228-32.
10381903	Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999 Jul;117(1):7-10.
10930381	Teich N, Ockenga J, Hoffmeister A, Manns M, Mossner J, Keim V: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology. 2000 Aug;119(2):461-5.
11788572	Pfutzer R, Myers E, Applebaum-Shapiro S, Finch R, Ellis I, Neoptolemos J, Kant JA, Whitcomb DC: Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002 Feb;50(2):271-2.
2598466	Kimland M, Russick C, Marks WH, Borgstrom A: Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta. 1989 Sep 15;184(1):31-46.
3011602	Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 1986;41(2-3):305-10.
8683601	Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC: Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol. 1996 Jun 28;259(5):995-1010.
8841182	Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996 Oct;14(2):141-5.
9322498	Gorry MC, Gabbaizedeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997 Oct;113(4):1063-8.
9633818	Teich N, Mossner J, Keim V: Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mutat. 1998;12(1):39-43.

# Drug_Target_1_HGNC_ID:
HGNC:9475

# Drug_Target_1_HPRD_ID:
02039

# Drug_Target_1_ID:
3176

# Drug_Target_1_Locus:
7q32-qter|7q34

# Drug_Target_1_Molecular_Weight:
26558

# Drug_Target_1_Name:
Trypsin-1

# Drug_Target_1_Number_of_Residues:
247

# Drug_Target_1_PDB_ID:
1TRN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_1_Protein_Sequence:
>Trypsin-1 precursor
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS

# Drug_Target_1_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_1_Signals:
1-15

# Drug_Target_1_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_1_SwissProt_ID:
P07477

# Drug_Target_1_SwissProt_Name:
TRY1_HUMAN

# Drug_Target_1_Synonyms:
Cationic trypsinogen
EC 3.4.21.4
Serine protease 1
Trypsin I
Trypsin-1 precursor

# Drug_Target_1_Theoretical_pI:
6.48

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein. Note=Released from the secretory granules upon mast cell activation

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
TPSB2

# Drug_Target_2_GenBank_ID_Gene:
M37488

# Drug_Target_2_GenBank_ID_Protein:
179584

# Drug_Target_2_GeneCard_ID:
TPSB2

# Drug_Target_2_Gene_Name:
TPSB2

# Drug_Target_2_Gene_Sequence:
>828 bp
ATGCTGAATCTGCTGCTGCTGGCGCTGCCCGTCCTGGCGAGCCGCGCCTACGCGGCCCCT
GCCCCAGGCCAGGCCCTGCAGCGAGTGGGCATCGTTGGGGGTCAGGAGGCCCCCAGGAGC
AAGTGGCCCTGGCAGGTGAGCCTGAGAGTCCACGGCCCATACTGGATGCACTTCTGCGGG
GGCTCCCTCATCCACCCCCAGTGGGTGCTGACCGCAGCGCACTGCGTGGGACCGGACGTC
AAGGATCTGGCCGCCCTCAGGGTGCAACTGCGGGAGCAGCACCTCTACTACCAGGACCAG
CTGCTGCCGGTCAGCAGGATCATCGTGCACCCACAGTTCTACACCGCCCAGATCGGAGCG
GACATCGCCCTGCTGGAGCTGGAGGAGCCGGTGAAGGTCTCCAGCCACGTCCACACGGTC
ACCCTGCCCCCTGCCTCAGAGACCTTCCCCCCGGGGATGCCGTGCTGGGTCACTGGCTGG
GGCGATGTGGACAATGATGAGCGCCTCCCACCGCCATTTCCTCTGAAGCAGGTGAAGGTC
CCCATAATGGAAAACCACATTTGTGACGCAAAATACCACCTTGGCGCCTACACGGGAGAC
GACGTCCGCATCGTCCGTGACGACATGCTGTGTGCCGGGAACACCCGGAGGGACTCATGC
CAGGGCGACTCCGGAGGGCCCCTGGTGTGCAAGGTGAATGGCACCTGGCTGCAGGCGGGC
GTGGTCAGCTGGGGCGAGGGCTGTGCCCAGCCCAACCGGCCTGGCATCTACACCCGTGTC
ACCTACTACTTGGACTGGATCCACCACTATGTCCCCAAAAAGCCGTGA

# Drug_Target_2_General_Function:
Involved in protease activity

# Drug_Target_2_General_References:
10500112	Sommerhoff CP, Bode W, Pereira PJ, Stubbs MT, Sturzebecher J, Piechottka GP, Matschiner G, Bergner A: The structure of the human betaII-tryptase tetramer: fo(u)r better or worse. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10984-91.
2187193	Vanderslice P, Ballinger SM, Tam EK, Goldstein SM, Craik CS, Caughey GH: Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci U S A. 1990 May;87(10):3811-5.
2203827	Miller JS, Moxley G, Schwartz LB: Cloning and characterization of a second complementary DNA for human tryptase. J Clin Invest. 1990 Sep;86(3):864-70.
8434231	Blom T, Hellman L: Characterization of a tryptase mRNA expressed in the human basophil cell line KU812. Scand J Immunol. 1993 Feb;37(2):203-8.
9521329	Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, Sommerhoff CP, Bode W: Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature. 1998 Mar 19;392(6673):306-11.
9920877	Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH: Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3. J Biol Chem. 1999 Feb 5;274(6):3355-62.

# Drug_Target_2_HGNC_ID:
HGNC:14120

# Drug_Target_2_HPRD_ID:
10277

# Drug_Target_2_ID:
2686

# Drug_Target_2_Locus:
16p13.3

# Drug_Target_2_Molecular_Weight:
30515

# Drug_Target_2_Name:
Tryptase beta-2

# Drug_Target_2_Number_of_Residues:
275

# Drug_Target_2_PDB_ID:
2BM2

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_2_Protein_Sequence:
>Tryptase beta-2 precursor
MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHFCG
GSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGA
DIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKV
PIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAG
VVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP

# Drug_Target_2_Reaction:
Preferential cleavage: Arg!, Lys!, but with more restricted specificity than trypsin

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type

# Drug_Target_2_SwissProt_ID:
P20231

# Drug_Target_2_SwissProt_Name:
TRYB2_HUMAN

# Drug_Target_2_Synonyms:
EC 3.4.21.59
Tryptase II
Tryptase beta-2 precursor
Tryptase-2

# Drug_Target_2_Theoretical_pI:
7.12

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04654
